Acura Pharmaceuticals Announces $200K Loan, Warns of Potential Layoffs

What Happened
Acura Pharmaceuticals filed an 8‑K on July 24, 2026 disclosing it received a $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026. That loan, together with prior borrowings and amounts under the Nov. 10, 2022 amended secured promissory note, brings the principal balance to $10,894,279 with accrued interest of approximately $1,200,000 as of July 17, 2026. The consolidated note bears interest at 5.25% and contains default provisions (including bankruptcy, inability to pay debts, and missed payments), with overdue amounts accruing default interest at 7.5% per annum.

Key Details

• $200,000 new loan received from Abuse Deterrent Pharma, LLC on July 17, 2026.
• Combined principal: $10,894,279; accrued interest ≈ $1,200,000 (as of July 17, 2026).
• Interest rate: 5.25% (7.5% on overdue amounts). Events of default include bankruptcy and failure to pay within 5 days.
• Company says funds were used for day‑to‑day operations and warns that without additional financing by mid‑August 2026 it will need to scale back operations, furlough or lay off employees, or possibly seek bankruptcy protection; the agreement includes key December 31, 2026 deadlines related to NDA acceptance and note payoff.

Why It Matters
This filing signals acute liquidity pressure: Acura has added short‑term debt and faces sizable outstanding secured obligations and accrued interest. The company expressly warns that failure to secure additional financing quickly could force operational cutbacks, workforce reductions, or bankruptcy — outcomes that could substantially harm or eliminate shareholder value. Investors should track any financing developments, covenant/default notices, and material updates on the December 31, 2026 deadlines and FDA/NDA milestones (e.g., LTX‑03) referenced in the filing.